Efficacy and safety of linzagolix for the treatment of heavy menstrual bleeding due to uterine fibroids: Results from two Phase 3 randomized clinical trials
October 22, 2020
Linzagolix
Elizabeth A. Stewart, MD; Hugh S. Taylor, MD; Robert N. Taylor, MD, PhD; Jacques Donnez, PhD, MD; Elke Bestel, MD; Jean-Pierre Gotteland, PhD; Andrew Humberstone, PhD; Elizabeth Garner, MD, MPH
ASRM 2020 Virtual Congress, October 2020
Poster session, Late-breaking abstract – Poster P. 930, page e527
Read moreLinzagolix may address the long-term treatment needs of women with uterine fibroids who have contraindications to hormonal add-back therapy: results from two Phase 3 randomized clinical trials
Linzagolix
Linda D. Bradley, MD; Erica E. Marsh, MD, MSCI, FACOG; Elizabeth Garner, MD, MPH
ASRM 2020 Virtual Congress, October 2020
Poster session, Late-breaking abstract – Poster P. 931, page e527
Read moreFibroids and medical therapy: bridging the gap from selective progesterone receptor modulators to gonadotropin-releasing hormone antagonist
October 12, 2020
Linzagolix
Jacques Donnez, M.D., Ph.D., Marie-Madeleine Dolmans, M.D., Ph.D.
Fertility and Sterility, Volume 114, Issue 4, 2020, Pages 739-741
Read moreEfficacy and safety of linzagolix on heavy menstrual bleeding (HMB) due to uterine fibroids (UF): Results from a placebo-controlled, randomized, Phase 3 trial
July 13, 2020
Linzagolix
H. Taylor, J. Donnez, R. Taylor, E. Bestel, J.P. Gotteland, A. Humberstone, E. Garner
ESHRE 36th Virtual Annual Meeting, 5-8 July 2020
Human Reproduction, Volume 35, Issue Supplement_1, July 2020, on page i13
Read moreTreatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone–antagonist: a randomized clinical trial
June 4, 2020
Linzagolix
Jacques Donnez, M.D., Ph.D., Hugh S. Taylor, M.D., Ph.D., Robert N. Taylor, M.D., Ph.D., Mark D. Akin, M.D., Tatyana F. Tatarchuk, M.D., Dr. Sc., Krzysztof Wilk, M.D., Jean-Pierre Gotteland, Ph.D., Veronique Lecomte, Pharm.D., Elke Bestel, M.D.
Published online: June 03, 2020
Read moreGonadotropin-releasing hormone antagonist (linzagolix): a new therapy for uterine adenomyosis
June 3, 2020
Linzagolix
Olivier Donnez M.D., Ph.D. , Jacques Donnez M.D., Ph.D.
Published online: June 02, 2020
Read moreLinzagolix for Endometriosis-Associated Pain: Lipid Changes After 52 Weeks of Treatment
April 24, 2020
Linzagolix
Bestel, Elke MD; Gotteland, Jean-Pierre PhD; Donnez, Jacques MD, PhD; Taylor, Robert N. MD, PhD; Garner, Elizabeth I. MD, MPH
ACOG Annual Conference, April 2020
Read moreQuality of Life Results After 52 Weeks of Treatment With Linzagolix for Endometriosis-Associated Pain
Linzagolix
Bestel, Elke MD; Gotteland, Jean-Pierre PhD; Donnez, Jacques MD, PhD; Taylor, Robert N. MD, PhD; Garner, Elizabeth I. MD, MPH
ACOG Annual Conference, April 2020
Read moreEffects of combined GnRH receptor antagonist linzagolix and hormonal add-back therapy on vaginal bleeding-delayed add-back onset does not improve bleeding pattern
February 26, 2020
Linzagolix
Pohl O., Marchand L., Bell D., Gotteland JP.
Read moreLong Term Treatment of Endometriosis Associated Pain (EAP) With Linzagolix: Efficacy and Safety After 12 Months of Treatment
October 7, 2019
Linzagolix
Taylor R., Bestel E., Gotteland JP., Lecomte V., Dubouloz R., Terrill P., Humberstone A., Loumaye E.
ASRM 2019 Scientific Congress & Expo, 12-16 October 2019, Philadelphia, PA
Fertility and Sterility Vol. 112, No. 3, Supplement, September 2019. Abstract on page e323.
Read more